Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for <i>KRAS</i> ‐Driven Cancer Therapy

L Lulu Zhang K Kang Han X Xiaozhe Wang (State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China) X Xiaolin Yu (China-Russia Belt and Road Joint Laboratory for Intelligent Chemistry and Advanced Materials of Liaoning Province, School of Chemistry) Y Yongqiang Zhang S Sihan He (State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China) Z Zhiwei Han Y Yushuang Liu (State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China) J Jun‐Cheng Su (Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China) School of Chemistry and Pharmaceutical Sciences Guangxi Normal University Guilin People's Republic of China) J Jun Zhou S Shengen Yi (Department of General Surgery The Second Xiang Ya Hospital of Central South University Changsha People's Republic of China) S Shengtao Xu (State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University) J Jinlei Bian (State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China) K Kewei Zheng (Xiangtan Central Hospital/Affiliated Hospital of Hunan University School of Biomedical Sciences Hunan University Changsha People's Republic of China) L Ling‐Yi Kong (State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China) K Kai‐Bo Wang (State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China)

Abstract

ABSTRACT Targeting oncogene promoter G‐quadruplexes (G4s) is a compelling therapeutic strategy against human malignancies. However, clinical progress has been hindered by the lack of potent and structurally diverse G4‐targeting ligands. Herein, using parallel KRAS proximal promoter G4 ( KRAS ‐G4) as a model system, we screened an in‐house natural product library and identified dehydroevodiamine (DEE) as a novel G4 stabilizer. Although DEE showed only modest anticancer activity, structural analyses determined its predominant binding mode to KRAS ‐G4. Leveraging these structural insights, we rationally designed and synthesized 15 DEE analogues. Among them, compound 7i emerged as the lead candidate, demonstrating a 9‐fold higher binding affinity and up to 20‐fold improvement in antiproliferative activity over DEE. We further determined the high‐resolution NMR structure of the KRAS ‐G4– 7i complex, uncovering a distinct dual‐binding mode, featuring extensive π–π stacking interactions with outer G‐tetrads and specific hydrogen bonding within groove regions. Functional analysis showed 7i effectively suppressed transcription of several G4‐containing oncogenes, induced genome‐wide G4 formation, and triggered DNA damage in colorectal cancer cells. Moreover, 7i significantly inhibited the growth of patient‐derived colorectal tumor organoids. Overall, our findings establish a structural framework for rational design of parallel G4‐targeting ligands and emphasize an alternative G4‐based therapeutic strategy for KRAS ‐driven cancers.

Article Details

Volume / Issue Vol. 65, Issue 32
Published August 03, 2026
ISSN 1433-7851
Publisher Wiley

Journal Info

Angewandte Chemie International Edition

Wiley

ISSN: 1433-7851 Physical Sciences

Authors (16)

L

Lulu Zhang

K

Kang Han

X

Xiaozhe Wang

State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China

X

Xiaolin Yu

China-Russia Belt and Road Joint Laboratory for Intelligent Chemistry and Advanced Materials of Liaoning Province, School of Chemistry

Y

Yongqiang Zhang

S

Sihan He

State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China

Z

Zhiwei Han

Y

Yushuang Liu

State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China

J

Jun‐Cheng Su

Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China) School of Chemistry and Pharmaceutical Sciences Guangxi Normal University Guilin People's Republic of China

J

Jun Zhou

S

Shengen Yi

Department of General Surgery The Second Xiang Ya Hospital of Central South University Changsha People's Republic of China

S

Shengtao Xu

State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University

J

Jinlei Bian

State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China

K

Kewei Zheng

Xiangtan Central Hospital/Affiliated Hospital of Hunan University School of Biomedical Sciences Hunan University Changsha People's Republic of China

L

Ling‐Yi Kong

State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China

K

Kai‐Bo Wang

State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China